a PNH clone. Sabine Cerny-Reiterer is recently deceased. Specific therapeutic options for patients suffering from AA and hMDS are limited. One treatment option is immunosuppressive therapy (IST) [1–4
Since their description and identification in leukemias and solid tumors, cancer stem cells (CSC) have been the subject of intensive research in translational oncology. Indeed, recent advances have led to the identification of CSC markers, CSC targets, and the preclinical and clinical evaluation of the CSC-eradicating (curative) potential of various drugs. However, although...
Since their description and identification in leukemias and solid tumors, cancer stem cells (CSC) have been the subject of intensive research in translational oncology. Indeed, recent advances have led to the identification of CSC markers, CSC targets, and the preclinical and clinical evaluation of the CSC-eradicating (curative) potential of various drugs. However, although...
Background Acute myeloid leukemia (AML) is a hematopoietic malignancy with a dismal outcome in the majority of cases. A detailed understanding of the genetic alterations and gene expression changes that contribute to its pathogenesis is important to improve prognostication, disease monitoring, and therapy. In this context, leukemia-associated misexpression of microRNAs (miRNAs...
Scholar Search for Marcel Scheideler in:PubMed • Google Scholar Search for Irena Vlatkovic in:PubMed • Google Scholar Search for Robert Kralovics in:PubMed • Google Scholar Search for Sabine Cerny ... -Reiterer in:PubMed • Google Scholar Search for Peter Valent in:PubMed • Google Scholar Search for Heinz Sill in:PubMed • Google Scholar Search for Rotraud Wieser in:PubMed • Google Scholar Corresponding
Systemic mastocytosis either presents as aggressive neoplasm with short survival time or indolent systemic mastocytosis with normal life expectancy. In both instances, neoplastic mast cells usually harbor the D816V-mutated variant of KIT. Phenotypically, mast cells in systemic mastocytosis usually express CD25. However, no robust marker that discriminates between aggressive and...
Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) is in part driven by the tyrosine kinase bcr-abl, but imatinib does not produce long-term remission. Therefore, second-generation ABL inhibitors are currently in clinical investigation. Considering different target specificities and the pronounced genetic heterogeneity of Ph+ ALL, which contributes to the...
